# US 2025/0057867 A1 · Nucleoside phosphoramidates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0057867 A1
- Document ID: US20250057867A1
- Status: Published application
- Kind: A1
- Application number: 18/589,387
- Filed: 2024-02-27
- Published: 2025-02-20
- Earliest claimed: 2009-05-20
- Assignees: Gilead Sciences, Inc.
- Applicants: Gilead Sciences, Inc.
- Inventors: Bruce S. Ross; Michael Joseph Sofia; Ganapati Reddy Pamulapati; Suguna Rachakonda; Hai-Ren Zhang; Byoung-Kwon Chun; Peiyuan Wang
- Web page: https://patentgrep.com/patent/US20250057867A1

## CPC

- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/14: for RNA viruses
- C07F 9/2479: {Compounds containing the structure P(=X)n-N-acyl, P(=X)n-N-heteroatom, P(=X)n-N-CN (X = O, S, Se; n = 0, 1)}
- C07H 19/06: Pyrimidine radicals
- C07H 19/10: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H 23/00: Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12 (esters with inorganic acids C07H11/00)
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.

## Claims

### Claim 1

Crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate.

### Claim 2

Crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate having:
(1) XRPD 2θ-reflections (°) at about: 5.2, 7.5, 9.6, 16.7, 18.3, and 22.2;
(2) XRPD 2θ-reflections (°) at about: 5.0, 7.3, 9.4, and 18.1;
(3) XRPD 2θ-reflections (°) at about: 4.9, 6.9, 9.8, 19.8, 20.6, 24.7, and 26.1;
(4) XRPD 2θ-reflections (°) at about: 6.9, 9.8, 19.7, 20.6, and 24.6;
(5) XRPD 2θ-reflections (°) at about: 5.0, 6.8, 19.9, 20.6, 20.9, and 24.9;
(6) XRPD 2θ-reflections (°) at about: 5.2, 6.6, 7.1, 15.7, 19.1, and 25.0; or
(7) XRPD 2θ-reflections (°) at about: 6.1, 8.2, 10.4, 12.7, 17.2, 17.7, 18.0, 18.8, 19.4, 19.8, 20.1, 20.8, 21.8, and 23.3.

### Claim 3 (depends on 2)

Crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate of claim 2 having:
(1) XRPD 2θ-reflections (°) at about: 5.2, 7.5, 9.6, 16.7, 18.3, and 22.2;
(2) XRPD 2θ-reflections (°) at about: 5.0, 7.3, 9.4, and 18.1; or
(7) XRPD 2θ-reflections (°) at about: 6.1, 8.2, 10.4, 12.7, 17.2, 17.7, 18.0, 18.8, 19.4, 19.8, 20.1, 20.8, 21.8, and 23.3.

### Claim 4 (depends on 2)

Crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate of claim 2 having:
(1) XRPD 2θ-reflections (°) at about: 5.2, 7.5, 9.6, 16.7, 18.3, and 22.2;
(2) XRPD 2θ-reflections (°) at about: 5.0, 7.3, 9.4, and 18.1; or
(7) XRPD 2θ-reflections (°) at about: 6.1, 8.2, 10.4, 12.7, 17.2, 17.7, 18.0, 18.8, 19.4, 19.8, 20.1, 20.8, 21.8, and 23.3.

### Claim 5 (depends on 2)

Crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate of claim 2 having XRPD 2θ-reflections (°) at about: 5.2, 7.5, 9.6, 16.7, 18.3, and 22.2.

### Claim 6 (depends on 2)

Crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate of claim 2 having XRPD 2θ-reflections (°) at about: 5.0, 7.3, 9.4, and 18.1.

### Claim 7 (depends on 2)

Crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate of claim 2 having XRPD 2θ-reflections (°) at about: 6.1, 8.2, 10.4, 12.7, 17.2, 17.7, 18.0, 18.8, 19.4, 19.8, 20.1, 20.8, 21.8, and 23.3.

### Claim 8 (depends on 1)

A composition comprising crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate of claim 1.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate of claim 1 and a pharmaceutically acceptable medium.

### Claim 10 (depends on 1)

A method of treating a hepatitis C virus infection in a subject in need thereof, which comprises:
administering to the subject an effective amount of crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate of claim 1.

### Claim 11

A compound represented by the structural formula
where LG′ is a leaving group.

### Claim 12 (depends on 11)

The compound of claim 11, wherein LG′ is tosylate, camphorsulfonate, a benzo[d]thiazolide-2(3H)-thione, an aryloxide, or an aryloxide substituted with at least one electron withdrawing group.

### Claim 13 (depends on 11)

The compound of claim 11, wherein LG′ is 2,4-dinitrophenoxide, 4-nitrophenoxide, 2-nitrophenoxide, 2-chloro-4-nitrophenoxide, 2,4-dichlorophenoxide, or pentafluorophenoxide.

### Claim 14

(S)-isopropyl 2-(((S)-(perfluorophenoxy)(phenoxy)phosphoryl)amino) propanoate.

### Claim 15

Crystalline (S)-isopropyl 2-(((S)-(perfluorophenoxy)(phenoxy) phosphoryl)amino)propanoate.

### Claim 16 (depends on 11)

A process for preparing the compound of claim 11, which comprises:
crystallizing the compound from a composition, comprising
a) a first composition;
b) a second leaving group precursor;
c) a non-nucleophilic base; and
d) a liquid composition;
wherein the first composition comprises the compound and its corresponding P-based diastereomer.

### Claim 17 (depends on 16)

The process of claim 16, wherein the mole amount of the compound and the mole amount of its P-based diastereomer are the same or different.

### Claim 18 (depends on 17)

The process claim 17, wherein the mole amount of the compound is greater than the mole amount of its corresponding P-based diastereomer.

### Claim 19 (depends on 16)

The process of claim 16, wherein the second leaving group precursor is 2,4-dinitrophenol, 4-nitrophenol, 2-nitrophenol, 2-chloro-4-nitrophenol, 2,4-dichlorophenol, or pentafluorophenol.

### Claim 20 (depends on 19)

The process of claim 19, wherein LG′ is pentafluorophenoxide.

### Claim 21 (depends on 20)

The process of claim 20, wherein the second leaving group precursor is pentafluorophenol.

### Claim 22 (depends on 21)

The process of claim 21, wherein the amount of pentafluorophenol ranges from about 0.01 mole equivalents to about 10 mole equivalents relative to the mole amount of the compound and its P-based diastereomer.

### Claim 23 (depends on 21)

The process of claim 21, wherein the amount of pentafluorophenol ranges from about 0.1 mole equivalents to about 1 mole equivalents relative to the mole amount of the compound and its P-based diastereomer.

### Claim 24 (depends on 16)

The process of claim 16, wherein the crystallizing occurs at a temperature that ranges from about −10° C. to about +40° C.

### Claim 25 (depends on 16)

The process of claim 16, wherein the crystallizing occurs at about room temperature.

### Claim 26 (depends on 16)

The process of claim 16, wherein the non-nucleophilic base is selected from among potassium carbonate, cesium carbonate, di-isopropylamine, di-isopropylethylamine, triethylamine, quinuclidine, naphthalene-1,8-diamine, 2,2,6,6-tetramethylpiperidine, 1,8-diazabicycloundec-7-ene, 4-dimethylamino-pyridine, pyridine, a 2,6-di-C1-6-alkyl-pyridine, a 2,4,6-tri-C1-6-alkyl-pyridine, and mixtures thereof.

### Claim 27 (depends on 16)

The process of claim 16, wherein the non-nucleophilic base is triethylamine.

### Claim 28 (depends on 16)

The process of claim 16, wherein the non-nucleophilic base is present in an amount that ranges from about 0.01 equivalents mol to about 10 mol equivalents relative to the total mole amount of the compound and its P-based diastereomer.

### Claim 29 (depends on 16)

The process of claim 16, wherein the non-nucleophilic base is present in an amount that ranges from about 0.1 mol equivalents to about 1 mol equivalents relative to the total mole amount of the compound and its P-based diastereomer.

### Claim 30 (depends on 16)

The process of claim 16, wherein the solubility of the compound is less than the solubility of its corresponding P-based diastereomer in the liquid composition.

### Claim 31 (depends on 16)

The process of claim 16, wherein the liquid composition comprises at least one of a solvent and an anti-solvent.

### Claim 32 (depends on 16)

The process of claim 16, wherein the liquid composition comprises at least one of a C1 to C8 alcohol, a C2 to C8 ether, a C3 to C7 ketone, a C3 to C7 ester, a C1 to C2 chlorocarbon, a C2 to C7 nitrile, a C5 to C12 saturated hydrocarbon, and a C6 to C12 aromatic hydrocarbon.

### Claim 33 (depends on 16)

The process of claim 16, wherein the liquid composition comprises at least one of a C2 to C8 ether, a C3 to C7 ester, a C5 to C12 saturated hydrocarbon, and a C6 to C12 aromatic hydrocarbon.

### Claim 34 (depends on 16)

The process of claim 16, wherein the liquid composition comprises at least one of a C2 to C8 ether, a C3 to C7 ester, and a C5 to C12 saturated hydrocarbon.

### Claim 35 (depends on 34)

The process of claim 34, wherein the liquid composition comprises at least one of ethyl acetate, t-butyl-methylether, and hexane.

### Claim 36 (depends on 34)

The process of claim 34, wherein the liquid composition comprises ethyl acetate and hexane.

### Claim 37 (depends on 34)

The process of claim 34, wherein the liquid composition comprises t-butyl-methylether and hexane.

### Claim 38 (depends on 16)

The process of claim 16, wherein the amount of liquid composition ranges from about 1 mL to about 10 mL for every gram of the first composition.

### Claim 39 (depends on 16)

The process of claim 16, which further comprises adding crystalline compound to the composition.

### Claim 40 (depends on 16)

The process of claim 16, which further comprises adding about 0.1 to about 1 wt. % of crystalline compound to the first composition.

### Claim 41 (depends on 16)

The process of claim 16, which further comprises
a) reacting PhOP(O)(LG)2 and iPr-Ala-NH2HCl in the presence of a first base to obtain (PhO)P(O)(LG)(NHAla-iPr);
b) reacting (PhO)P(O)(LG)(NHAla-iPr) with a first leaving group precursor (LG′H) in the presence of a second base to obtain the composition comprising the compound and its P-based diastereomer;
wherein LG and LG′, independent of each other, are leaving groups;
wherein the first leaving group precursor and the second leaving group precursor are the same or different; and
wherein the first base and the second base are the same or different.

### Claim 42

A process for preparing crystalline (S)-isopropyl 2-(((S)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate, which comprises:
crystallizing (S)-isopropyl 2-(((S)-(perfluorophenoxy)(phenoxy)phosphoryl) amino)propanoate from a second composition comprising
a) a first composition;
b) pentafluorophenol;
c) a non-nucleophilic base; and
d) a liquid composition;
wherein the second composition comprises (S)-isopropyl 2-(((S)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate and (S)-isopropyl 2-(((R)-(perfluorophenoxy)(phenoxy)phosphoryl)amino) propanoate.

### Claim 43 (depends on 42)

The process of claim 42, wherein the mole amount of the (S)-isopropyl 2-(((S)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate and the mole amount of (S)-isopropyl 2-(((R)-(perfluorophenoxy)(phenoxy)phosphoryl)amino) propanoate are the same or different.

### Claim 44 (depends on 42)

The process of claim 42, wherein the mole amount of the (S)-isopropyl 2-(((S)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate is greater than the mole amount of (S)-isopropyl 2-(((R)-(perfluorophenoxy)(phenoxy)phosphoryl) amino)propanoate.

### Claim 45 (depends on 43)

The process of claim 43, wherein the amount of pentafluorophenol ranges from about 0.01 mole equivalents to about 10 mole equivalents relative to the mole amount of (S)-isopropyl 2-(((S)-(perfluorophenoxy)(phenoxy)phosphoryl) amino)propanoate and (S)-isopropyl 2-(((R)-(perfluorophenoxy)(phenoxy) phosphoryl)amino)propanoate.

### Claim 46 (depends on 42)

The process of claim 42, wherein the crystallizing occurs at a temperature that ranges from about −10° C. to about +40° C.

### Claim 47 (depends on 42)

The process of claim 42, wherein the crystallizing occurs at about room temperature.

### Claim 48 (depends on 42)

The process of claim 42, wherein the non-nucleophilic base is selected from among potassium carbonate, cesium carbonate, di-isopropylamine, di-isopropylethylamine, triethylamine, quinuclidine, naphthalene-1,8-diamine, 2,2,6,6-tetramethylpiperidine, 1,8-diazabicycloundec-7-ene, 4-dimethylamino-pyridine, pyridine, a 2,6-di-C1-6-alkyl-pyridine, a 2,4,6-tri-C1-6-alkyl-pyridine, and mixtures thereof.

### Claim 49 (depends on 42)

The process of claim 42, wherein the non-nucleophilic base is triethylamine.

### Claim 50 (depends on 42)

The process of claim 42, wherein the non-nucleophilic base is present in an amount that ranges from about 0.1 to about 1 mol equivalents relative to the total mole amount of (S)-isopropyl 2-(((S)-(perfluorophenoxy)(phenoxy)phosphoryl) amino)propanoate and (S)-isopropyl 2-(((R)-(perfluorophenoxy)(phenoxy) phosphoryl)amino)propanoate.

### Claim 51 (depends on 42)

The process of claim 42, wherein the solubility of (S)-isopropyl 2-(((S)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate is less than the solubility of (S)-isopropyl 2-(((R)-(perfluorophenoxy)(phenoxy)phosphoryl)amino) propanoate in the liquid composition.

### Claim 52 (depends on 42)

The process of claim 42, wherein the liquid composition comprises at least one of a solvent and an anti-solvent.

### Claim 53 (depends on 42)

The process of claim 42, wherein the liquid composition comprises at least one of a C1 to C8 alcohol, a C2 to C8 ether, a C3 to C7 ketone, a C3 to C7 ester, a C1 to C2 chlorocarbon, a C2 to C7 nitrile, a C5 to C12 saturated hydrocarbon, and a C6 to C12 aromatic hydrocarbon.

### Claim 54 (depends on 42)

The process of claim 42, wherein the liquid composition comprises at least one of a C2 to C8 ether, a C3 to C7 ester, a C5 to C12 saturated hydrocarbon, and a C6 to C12 aromatic hydrocarbon.

### Claim 55 (depends on 42)

The process of claim 42, wherein the liquid composition comprises at least one of a C2 to C8 ether, a C3 to C7 ester, and a C5 to C12 saturated hydrocarbon.

### Claim 56 (depends on 55)

The process of claim 55, wherein the liquid composition comprises at least one of ethyl acetate, t-butyl-methylether, and hexane.

### Claim 57 (depends on 55)

The process of claim 55, wherein the liquid composition comprises ethyl acetate and hexane.

### Claim 58 (depends on 55)

The process of claim 55, wherein the liquid composition comprises t-butyl-methylether and hexane.

### Claim 59 (depends on 42)

The process of claim 42, wherein the amount of liquid composition ranges from about 1 to about 10 mL for every gram of the first composition.

### Claim 60 (depends on 42)

The process of claim 42, which further comprises adding crystalline (S)-isopropyl 2-(((S)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate to the second composition.

### Claim 61 (depends on 42)

The process of claim 42, which further comprises adding about 0.1 to about 1 wt. % of crystalline (S)-isopropyl 2-(((S)-(perfluorophenoxy)(phenoxy) phosphoryl)amino)propanoate based on the total weight of (S)-isopropyl 2-(((S)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate in the first composition.

### Claim 62 (depends on 42)

Crystalline (S)-isopropyl 2-(((S)-(perfluorophenoxy)(phenoxy) phosphoryl)amino)propanoate obtained by the process of claim 42.

### Claim 63

A process for preparing (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate, which comprises:
crystallizing (S)-isopropyl 2-(((S)-(perfluorophenoxy)(phenoxy)phosphoryl) amino)propanoate from a second composition comprising
a) a first composition;
b) pentafluorophenol;
c) a non-nucleophilic base; and
d) a liquid composition;
wherein the first composition comprises (S)-isopropyl 2-(((S)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate and (S)-isopropyl 2-(((R)-(perfluorophenoxy)(phenoxy)phosphoryl)amino) propanoate.

### Claim 64

A process for preparing (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate, which comprises:
contacting (S)-isopropyl 2-(((S)-(perfluorophenoxy)(phenoxy)phosphoryl) amino)propanoate with a product obtained by reacting a t-butylmagnesium halide with 1-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione with a t-butylmagnesium halide.

### Claim 65 (depends on 64)

The process of claim 64, wherein the contacting occurs in a medium having a temperature that ranges from about 0° C. to about 40° C.

### Claim 66 (depends on 64)

The process of claim 64, wherein the contacting occurs in a medium having a temperature that ranges from about 0° C. to about 30° C.

### Claim 67 (depends on 64)

The process of claim 64, wherein the mole ratio of t-butylmagnesium halide to 1-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione ranges from about 2 to about 2.2.

### Claim 68 (depends on 64)

The process of claim 64, wherein the mole ratio of t-butylmagnesium halide to 1-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione is about 2.1.

### Claim 69 (depends on 64)

The process of claim 64, wherein the t-butylmagnesium halide is t-butylmagnesium chloride.

### Claim 70 (depends on 35)

A process for preparing substantially pure (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate, which comprises:
obtaining (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate according to the process of claim 35 and
crystallizing the so-formed (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate.
